Foreign-manufactured research-use-only peptides have long posed safety concerns for American patients, and Washington has now moved to address that vulnerability directly.
The Department of Health and Human Services issued a formal enforcement discretion policy on October 28, 2026, covering six specific peptide bulk drug substances used in compounding pharmacies.
The compounds named in the policy are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, which have been proposed for treating conditions ranging from wound healing and osteoporosis to obesity, insomnia, and inflammatory diseases.
Under the new framework, HHS will not pursue enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding drugs from these six substances, provided all specified circumstances are satisfied.
Crucially, none of the six peptides currently meets the formal conditions required for inclusion on the FDA’s 503A Bulks List, the official register of bulk drug substances permitted for pharmacy compounding.
That regulatory gap has left patients relying on an uncontrolled market, with supply chains frequently traced back to foreign manufacturers whose products carry unverified safety profiles.
The policy’s stated rationale goes directly to that concern: “This limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients. By allowing limited compounding of the substances addressed in this guidance under appropriate safeguards, the policy provides patients with a more controlled alternative.”
The groundwork for the decision was laid earlier this year when the FDA’s Pharmacy Compounding Advisory Committee voted in favour of recommending all six peptides for addition to the 503A Bulks List at a two-day meeting held in July.
Despite that advisory backing, the formal rulemaking process required to place the compounds on the list has not concluded, making the enforcement discretion mechanism a bridging measure rather than a permanent resolution.
HHS confirmed the policy will remain operative only until the FDA completes the rulemaking process necessary to establish a formal 503A Bulks List entry for these substances.
That timeline remains undefined, meaning compounders operating under the policy’s protections must continue monitoring regulatory developments to assess when formal rules will supersede the current arrangement.
For pharmacies and physicians already working with these compounds, the practical effect is meaningful: qualified compounders operating within the policy’s conditions now have a degree of federal cover that did not exist before October 28.
Legal analysts at Foley and Lardner LLP noted that the announcement was highly anticipated, reflecting months of uncertainty across the compounding sector about how federal authorities would treat these widely used but formally unclassified peptide substances.